Zentalis Pharmaceuticals (ZNTL) announced the appointment of Kimberly Freeman as Chief Strategy Officer. In this role, she will support and implement Zentalis’ long-term portfolio strategy. Freeman joins Zentalis with over 25 years of clinical development and strategic leadership experience, including deep expertise in oncology, particularly in gynecologic malignancies and the DNA damage response pathway. Prior to joining Zentalis, Freeman was Vice President, US Head of DDR Franchise, Oncology at AstraZeneca (AZN)
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZNTL:
- Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Acrivon appoints Levy as SVP, head, investor relations and corporate affairs
- Fly Insider: Howard Hughes, Crowdstrike among week’s notable insider trades
- Zentalis management to meet with Oppenheimer
- Take a Look at Zentalis Stock’s (NASDAQ:ZNTL) Enormous Insider Trade